Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is trading lower on Thursday after the company released data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback